title: Pitviper Envenomation Guidelines Should Address Choice Between FDA-approved Treatments for Cases at Risk of Late Coagulopathy.
authors.affiliation: VIPER Institute, University of Arizona, Tucson, Arizona.
authors.forename: Leslie V
authors.initials: LV
authors.lastname: Boyer
authors.affiliation: Banner - University Medical Center Phoenix, Phoenix Arizona.
authors.forename: Anne-Michelle
authors.initials: AM
authors.lastname: Ruha
mesh_terms: D000997:Antivenins / Q000627:therapeutic use*; D003435:Crotalid Venoms / Q000506:poisoning; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control; D004635:Emergency Medicine / Q000379:methods; D017408:Guidelines as Topic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D012909:Snake Bites / Q000150:complications* / Q000188:drug therapy* / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration; D014757:Viper Venoms / Q000506:poisoning
chemical_list: D000997:Antivenins; D003435:Crotalid Venoms; C431183:Crotalidae Polyvalent immune Fab; D007140:Immunoglobulin Fab Fragments; D014757:Viper Venoms